Casanueva-Calero K, Pantaleón-Florido G, Ruiz-Noa Y, Mato-Luis J, Quesada-Dorta M, Carnot-Uria J

Language: Spanish
References: 28
Page: 243-248
PDF size: 94.28 Kb.

ABSTRACT

Background: Chronic myeloid leukemia (CML) represents 15% of leukemias in adults. Its early recognition from other myeloproliferative syndromes is fundamental for beginning treatment and increasing chances for a favorable outcome. Detection of Philadelphia chromosome or the subjacent BCR-ABL rearrangement is necessary to confirm the diagnosis of CML. But BCR-ABL determination by reverse transcription and polymerase chain reaction is a more sensitive method.
Material and method: Here we applied a qualitative variant of that methodology for BCR-ABL detection in 27 patients with CML diagnosis.
Results: Out of total patients 93% was positive to BCR-ABL, confirming the diagnosis of CML. BCR-ABL transcripts b3a2, b2a2, and e1a2 were found in 60%, 32% and 8% of positive patients, respectively. Gender analysis revealed a greater presence of b2a2 in women (40%) than in men (27%). Variant e1a2 was exclusively detected in the latter. No co-expression of the transcripts tested was found.
Conclusions: These results support the diagnostic utility of the methodology employed and warrant the evaluation of a higher amount of CML patients for corroborating the genetic frequencies encountered and assessing their relationship with prognostic parameters.

REFERENCES

1. Quintas-Cardama A, Cortes JA. Chronic Myeloid Leukemia: Diagnosis and Treatment. Mayo Clinic Proceedings 2006;81:973-988.

2. Testoni N, Marzocchi G, Luatti S, Amabile M, et al. Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood 2009;114:4939-4943.

3. Goldman J, Melo J. Chronic myeloid leukemia. Advances in biology and new approaches to treatment. N Engl J Med 2003;349:1451-1464.

4. Quintás-Cardama A, Cortes J. Molecular biology of BCR-ABL1- positive chronic myeloid leukemia. Blood 2009;113:1619-1630.

5. Chávez-González MA, Ayala-Sánchez M, Mayani M. La leucemia mieloide crónica en el siglo XXI: biología y tratamiento. Rev Invest Clin 2009;61:221-232.

6. Verma D, Kantarjian HM, Jones D, Luthra R, Borthakur G, et al. Chronic myeloid leukaemia (CML) with P190BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood 2009;114:2232-2235.

7. Sharma P, Kumar L, Mohanty S, Kochupillai V. Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts. Ann Hematol 2010;89:241-247.

8. Branford S, Hughes T. Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR. Methods Mol Med 2006;125:69-92.

9. Chomczynski P, Sacchhi N. Single-step method of ARN isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.

10. Dongen JJM, Macintyre EA, Gabert JA, Delabesse E, et al. Standardized RT-PCR analysis of fusion transcripts from chromosome aberrations in acute leukaemia for detection of minimal residual disease. Leukemia 1999;13:1901-1928.

11. Rerkamnuaychoke B, Kangwanpong D, Jootar S, Puranakanitstha C. Detection of BCR/ABL fusion gene in CML: a preliminary report. Southeast Asian J Trop Med Public Health 1995;26 Suppl 1:197-200.

12. Wells SJ, Phillips CN, Winton EF, Farhi DC. Reverse transcriptase-polymerase chain reaction for bcr/abl fusion in chronic myelogenous leukemia. Am J Clin Pathol 1996;105:756-760.

13. David M, Cross NC, Burgstaller S, Chase A, et al. Durable responses to imatinib in patients with PDGFRB fusion genepositive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 2007;109:61-64.

14. Cross NC, Reiter A. Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia 2002;16:1207-1212.

15. Hoteit R, Mahfouz R. Proposed algorithm for the best detection of different bcr-abl gene fusion transcripts in molecular diagnostics laboratories: experience of a major referral center. Genet Test Mol Biomarkers 2011;15:227-229.

16. Arana-Trejo RM, Ruiz Sánchez E, Ignacio-Ibarra G, Báez de la Fuente E, et al. BCR/ABL p210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML). Clin Lab Haematol 2002;24:145-150.

17. Polampalli S, Choughule A, Negi N, Shinde S, et al. Analysis and comparison of clinicohematological parameters and molecular and cytogenetic response of two Bcr/Abl fusion transcripts. Genet Mol Res 2008;7:1138-1149.

18. Mondal BC, Bandyopadhyay A, Majumdar S, Mukhopadhyay A, et al. Molecular profiling of chronic myeloid leukemia in Eastern India. Am J Hematol 2006;81:845-849.

19. Yaghmaie M, Ghaffari SH, Ghavamzadeh A, Alimoghaddam K, et al. Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia. Arch Iran Med 2008;11:247-251.

20. Goh HG, Hwang JY, Kim SH, Lee YH, et al. Comprehensive analysis of BCR-ABL transcript types in Korean CML patients using a newly developed multiplex RT-PCR. Transl Res 2006;148:249-256.

21. Shtalrid M, Talpaz M, Kurzrock R, Kantarjian H, et al. Analysis of breakpoints within the bcr gene and their correlation with the clinical course of Philadelphia-positive chronic myelogenous leukemia. Blood 1988;72:485-490.

22. Ruiz-Argüelles GJ, Garcés-Eisele J, Reyes-Núñez V, Ruiz- Delgado GJ. Frequencies of the breakpoint cluster region types of the BCR/ABL fusion gene in Mexican Mestizo patients with chronic myelogenous leukemia. Rev Invest Clin 2004;56:605-608.

23. Paz-y-Miño C, Burgos R, Morillo SA, Santos JC, et al. BCRABL rearrangement frequencies in chronic myeloid leukemia and acute lymphoblastic leukemia in Ecuador, South America. Cancer Genet Cytogenet 2002;132:65-67.

24. Melo RA, Melo FC, Lima DF, Seaffo MH, et al. Lack of clinical relevance of the type of chimeric mRNA in chronic myelogenous leukemia: a study of 90 patients. Blood 1997;90:219.

25. Yasunaga J, Matsuoka M. Leukemogenesis of adult T-cell leukemia. Int J Hematol 2003;78:312-320.

26. Mills KI, Benn P, Birnie GD. Does the breakpoint within the major breakpoint cluster region (M-bcr) influence the duration of the chronic phase in chronic myeloid leukemia? An analytical comparison of current literature. Blood 1991;78:1155-1161.

27. Osman EI, Hamad K, Fadl-Elmula IM, Ibrahim ME. Frequencies of BCR-ABL1 fusion transcripts among Sudanese chronic myeloid leukaemia patients Genet Mol Biol 2010;33:229-231.

28. Adler R, Viehmann S, Kuhlisch E, Martiniak Y, et al. Correlation of BCR/ABL transcript variants with patient´s characteristics in childhood chronic myeloid leukaemia. Eur J Haematol 2009;82:112-118.